DIVA Laboratories, Ltd. (TPEX:4153)
33.55
-0.35 (-1.03%)
Feb 11, 2026, 1:30 PM CST
DIVA Laboratories Balance Sheet
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Cash & Equivalents | 486.71 | 589.14 | 536.93 | 346.37 | 299.28 | 323.76 |
Trading Asset Securities | - | - | - | - | - | 3.92 |
Cash & Short-Term Investments | 486.71 | 589.14 | 536.93 | 346.37 | 299.28 | 327.67 |
Cash Growth | -10.89% | 9.72% | 55.02% | 15.73% | -8.67% | -41.55% |
Accounts Receivable | 290.14 | 262.41 | 203.13 | 281.89 | 190.37 | 188.14 |
Other Receivables | 31.54 | 23.45 | 10.08 | 19.55 | 13.31 | 8.2 |
Receivables | 321.68 | 285.86 | 213.2 | 301.44 | 203.68 | 196.35 |
Inventory | 226.99 | 151.42 | 196.21 | 319.3 | 352.32 | 250.19 |
Prepaid Expenses | - | 3.88 | 4.86 | 8.42 | 11.5 | 11.78 |
Other Current Assets | 9.33 | 0.75 | 5.21 | 0.86 | 7.8 | 5.55 |
Total Current Assets | 1,045 | 1,031 | 956.41 | 976.39 | 874.57 | 791.53 |
Property, Plant & Equipment | 217.34 | 222.96 | 231.46 | 225.57 | 227.56 | 232.92 |
Long-Term Investments | 6.48 | 5.03 | 4.61 | 6.32 | 30.94 | 35.45 |
Goodwill | - | - | - | - | 5.18 | 5.18 |
Other Intangible Assets | 1.06 | 1.71 | 0.74 | 1.31 | 4.41 | 6.91 |
Long-Term Deferred Tax Assets | 39.73 | 40.76 | 47.33 | 38.27 | 36.08 | 35.52 |
Other Long-Term Assets | 4.34 | 3.92 | 3.19 | 3.94 | 2.94 | 5.71 |
Total Assets | 1,314 | 1,305 | 1,244 | 1,252 | 1,182 | 1,113 |
Accounts Payable | 81.19 | 70.69 | 61.07 | 85.15 | 103.88 | 46.41 |
Accrued Expenses | 80.43 | 74.97 | 65.11 | 67.2 | 45.6 | 35.28 |
Current Portion of Leases | 2.58 | 2.47 | 2.53 | 0.13 | 0.13 | 0.13 |
Current Income Taxes Payable | 18.94 | 23.32 | 22.02 | 24.35 | 5.75 | 8.03 |
Current Unearned Revenue | 6.9 | 6.51 | 9.11 | 8.81 | 6.2 | 5.6 |
Other Current Liabilities | 123.44 | 68.95 | 43.47 | 48.95 | 30.72 | 27.28 |
Total Current Liabilities | 313.49 | 246.92 | 203.31 | 234.59 | 192.27 | 122.72 |
Long-Term Leases | 0.96 | 2.5 | 4.97 | 0.15 | 0.28 | 0.41 |
Pension & Post-Retirement Benefits | - | - | 0.19 | 0.87 | 2.69 | 0.91 |
Long-Term Deferred Tax Liabilities | 0.51 | 0.43 | 0.87 | - | 0.02 | 0.3 |
Other Long-Term Liabilities | 0.57 | 0.1 | 1.59 | - | - | - |
Total Liabilities | 315.52 | 249.94 | 210.93 | 235.62 | 195.27 | 124.34 |
Common Stock | 586.68 | 600.91 | 600.91 | 617.59 | 617.59 | 617.59 |
Additional Paid-In Capital | 347.14 | 382.33 | 393.58 | 400 | 400 | 400 |
Retained Earnings | 70.88 | 124.06 | 92.02 | 107.76 | 78.75 | 73.95 |
Treasury Stock | - | -45.99 | -45.99 | -99.91 | -99.91 | -99.91 |
Comprehensive Income & Other | -6.56 | -5.8 | -7.72 | -9.26 | -10 | -2.74 |
Total Common Equity | 998.14 | 1,056 | 1,033 | 1,016 | 986.42 | 988.89 |
Shareholders' Equity | 998.14 | 1,056 | 1,033 | 1,016 | 986.42 | 988.89 |
Total Liabilities & Equity | 1,314 | 1,305 | 1,244 | 1,252 | 1,182 | 1,113 |
Total Debt | 3.54 | 4.97 | 7.51 | 0.28 | 0.41 | 0.54 |
Net Cash (Debt) | 483.17 | 584.17 | 529.42 | 346.08 | 298.86 | 327.13 |
Net Cash Growth | -10.62% | 10.34% | 52.98% | 15.80% | -8.64% | -41.65% |
Net Cash Per Share | 8.20 | 9.91 | 8.99 | 5.88 | 5.08 | 4.91 |
Filing Date Shares Outstanding | 58.67 | 58.67 | 58.67 | 58.67 | 58.67 | 58.67 |
Total Common Shares Outstanding | 58.67 | 58.67 | 58.67 | 58.67 | 58.67 | 58.67 |
Working Capital | 731.23 | 784.13 | 753.1 | 741.8 | 682.3 | 668.81 |
Book Value Per Share | 17.01 | 17.99 | 17.60 | 17.32 | 16.81 | 16.86 |
Tangible Book Value | 997.08 | 1,054 | 1,032 | 1,015 | 976.83 | 976.8 |
Tangible Book Value Per Share | 17.00 | 17.96 | 17.59 | 17.30 | 16.65 | 16.65 |
Land | 154.92 | 154.92 | 154.92 | 154.92 | 154.92 | 154.92 |
Buildings | 85.42 | 85.42 | 85.42 | 85.42 | 85.42 | 85.42 |
Machinery | 75.04 | 91.36 | 90.79 | 86.84 | 84.46 | 83.14 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.